Abbott Laboratories Comprehensive Income 2010-2024 | ABT
Abbott Laboratories comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Abbott Laboratories comprehensive income for the quarter ending December 31, 2024 was $-7.906B, a 0.85% increase year-over-year.
- Abbott Laboratories comprehensive income for 2024 was $-7.906B, a 0.85% increase from 2023.
- Abbott Laboratories comprehensive income for 2023 was $-7.839B, a 2.63% decline from 2022.
- Abbott Laboratories comprehensive income for 2022 was $-8.051B, a 3.86% decline from 2021.
| Abbott Laboratories Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024 | $-7,906 |
| 2023 | $-7,839 |
| 2022 | $-8,051 |
| 2021 | $-8,374 |
| 2020 | $-8,946 |
| 2019 | $-8,465 |
| 2018 | $-7,586 |
| 2017 | $-6,062 |
| 2016 | $-7,263 |
| 2015 | $-6,658 |
| 2014 | $-5,053 |
| 2013 | $-2,012 |
| 2012 | $-3,594 |
| 2011 | $-2,597 |
| 2010 | $-1,367 |
| 2009 | $854 |
| Abbott Laboratories Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-12-31 | $-7,906 |
| 2024-09-30 | $-7,804 |
| 2024-06-30 | $-8,135 |
| 2024-03-31 | $-8,166 |
| 2023-12-31 | $-7,839 |
| 2023-09-30 | $-8,480 |
| 2023-06-30 | $-8,071 |
| 2023-03-31 | $-8,039 |
| 2022-12-31 | $-8,051 |
| 2022-09-30 | $-9,445 |
| 2022-06-30 | $-8,706 |
| 2022-03-31 | $-8,474 |
| 2021-12-31 | $-8,374 |
| 2021-09-30 | $-9,240 |
| 2021-06-30 | $-9,066 |
| 2021-03-31 | $-9,285 |
| 2020-12-31 | $-8,946 |
| 2020-09-30 | $-9,044 |
| 2020-06-30 | $-9,080 |
| 2020-03-31 | $-9,386 |
| 2019-12-31 | $-8,465 |
| 2019-09-30 | $-7,763 |
| 2019-06-30 | $-7,365 |
| 2019-03-31 | $-7,470 |
| 2018-12-31 | $-7,586 |
| 2018-09-30 | $-7,009 |
| 2018-06-30 | $-6,913 |
| 2018-03-31 | $-5,733 |
| 2017-12-31 | $-6,062 |
| 2017-09-30 | $-6,116 |
| 2017-06-30 | $-6,250 |
| 2017-03-31 | $-6,532 |
| 2016-12-31 | $-7,263 |
| 2016-09-30 | $-6,533 |
| 2016-06-30 | $-7,223 |
| 2016-03-31 | $-6,851 |
| 2015-12-31 | $-6,658 |
| 2015-09-30 | $-7,211 |
| 2015-06-30 | $-5,004 |
| 2015-03-31 | $-5,607 |
| 2014-12-31 | $-5,053 |
| 2014-09-30 | $-2,975 |
| 2014-06-30 | $-1,952 |
| 2014-03-31 | $-1,934 |
| 2013-12-31 | $-2,012 |
| 2013-09-30 | $-2,957 |
| 2013-06-30 | $-3,226 |
| 2013-03-31 | $-2,895 |
| 2012-12-31 | $-3,594 |
| 2012-09-30 | $-2,756 |
| 2012-06-30 | $-3,544 |
| 2012-03-31 | $-1,941 |
| 2011-12-31 | $-2,597 |
| 2011-09-30 | $-860 |
| 2011-06-30 | $578 |
| 2011-03-31 | $182 |
| 2010-12-31 | $-1,367 |
| 2010-09-30 | $-1,483 |
| 2010-06-30 | $-2,629 |
| 2010-03-31 | $-976 |
| 2009-12-31 | $854 |
| 2009-09-30 | $499 |
| 2009-06-30 | $-7 |
| 2009-03-31 | $-1,195 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $230.058B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $149.209B | 40.19 |
| Stryker (SYK) | United States | $142.084B | 30.54 |
| EssilorLuxottica (ESLOY) | France | $131.854B | 0.00 |
| Medtronic (MDT) | Ireland | $115.249B | 16.83 |
| Haleon (HLN) | United Kingdom | $46.488B | 26.39 |
| Lonza Group Ag (LZAGY) | Switzerland | $44.527B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $36.909B | 17.98 |
| Agilent Technologies (A) | United States | $33.351B | 22.03 |
| ResMed (RMD) | United States | $32.876B | 25.32 |
| Terumo (TRUMY) | Japan | $27.805B | 39.54 |
| Koninklijke Philips (PHG) | Netherlands | $23.874B | 17.05 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.530B | 14.15 |
| Insulet (PODD) | United States | $18.442B | 78.86 |
| Baxter (BAX) | United States | $17.557B | 12.63 |
| Sunny Optical Technology (SNPTF) | China | $12.864B | 0.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.403B | 0.00 |
| Demant (WILYY) | Denmark | $8.048B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.822B | 23.62 |
| Lantheus Holdings (LNTH) | United States | $6.684B | 16.43 |
| Prestige Consumer Healthcare (PBH) | United States | $4.259B | 20.32 |
| Perrigo (PRGO) | Ireland | $3.826B | 10.95 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.405B | 29.11 |
| Haemonetics (HAE) | United States | $3.193B | 15.02 |
| Envista Holdings (NVST) | United States | $2.972B | 23.64 |
| QuidelOrtho (QDEL) | United States | $2.359B | 19.76 |
| GN Store Nord (GNNDY) | Denmark | $2.336B | 15.74 |
| LeMaitre Vascular (LMAT) | United States | $1.893B | 43.25 |
| Neogen (NEOG) | United States | $1.881B | 21.67 |
| AtriCure (ATRC) | United States | $1.577B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.462B | 14.08 |
| Kestra Medical Technologies (KMTS) | $1.234B | 0.00 | |
| InMode (INMD) | Israel | $1.234B | 10.31 |
| Green Thumb Industries (GTBIF) | United States | $1.233B | 19.37 |
| BioLife Solutions (BLFS) | United States | $1.073B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.865B | 13.27 |
| Evolus (EOLS) | United States | $0.765B | 0.00 |
| Owens & Minor (OMI) | United States | $0.698B | 5.94 |
| CeriBell (CBLL) | United States | $0.689B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.601B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.562B | 0.00 |
| Valneva SE (VALN) | France | $0.545B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.478B | 20.71 |
| Omeros (OMER) | United States | $0.476B | 0.00 |
| Surmodics (SRDX) | United States | $0.436B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.433B | 0.00 |
| SNDL (SNDL) | Canada | $0.371B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.354B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.302B | 0.00 |
| ZimVie (ZIMV) | United States | $0.301B | 18.00 |
| Viemed Healthcare (VMD) | United States | $0.288B | 26.00 |
| Sanara MedTech (SMTI) | United States | $0.275B | 0.00 |
| Cerus (CERS) | United States | $0.258B | 0.00 |
| Quanterix (QTRX) | United States | $0.252B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.252B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.247B | 43.90 |
| Verano Holdings (VRNOF) | United States | $0.233B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.184B | 14.19 |
| Biote (BTMD) | United States | $0.182B | 4.16 |
| Brainsway (BWAY) | Israel | $0.178B | 55.71 |
| TriSalus Life Sciences (TLSI) | United States | $0.168B | 0.00 |
| High Tide (HITI) | Canada | $0.153B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.144B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.140B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.128B | 0.00 |
| Jin Medical (ZJYL) | China | $0.116B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.112B | 13.99 |
| Quipt Home Medical (QIPT) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Fonar (FONR) | United States | $0.087B | 12.18 |
| MacroGenics (MGNX) | United States | $0.080B | 0.00 |
| Veru (VERU) | United States | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.067B | 24.44 |
| United Health Products (UEEC) | United States | $0.066B | 0.00 |
| Exagen (XGN) | United States | $0.064B | 0.00 |
| InterCure (INCR) | Israel | $0.064B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.055B | 0.00 |
| Apyx Medical (APYX) | United States | $0.052B | 0.00 |
| Modular Medical (MODD) | United States | $0.044B | 0.00 |
| ImmuCell (ICCC) | United States | $0.043B | 0.00 |
| United-Guardian (UG) | United States | $0.041B | 12.66 |
| Rockwell Medical (RMTI) | United States | $0.038B | 56.50 |
| Safety Shot (SHOT) | United States | $0.027B | 0.00 |
| INLIF (INLF) | $0.021B | 0.00 | |
| Nephros (NEPH) | United States | $0.018B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |